8-K
false 0001757898 0001757898 2021-07-29 2021-07-29 0001757898 us-gaap:CommonStockMember 2021-07-29 2021-07-29 0001757898 ste:STETwo700SeniorNotesDue2031Member 2021-07-29 2021-07-29 0001757898 ste:Two700SeniorNotesDue2051Member 2021-07-29 2021-07-29

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 29, 2021

 

 

STERIS plc

(Exact Name of Registrant as Specified in Charter)

 

 

 

Ireland   001-38848   98-1455064

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

70 Sir John Rogerson’s Quay
Dublin 2, Ireland , D02 R296
(Address of Principal Executive Offices)

Registrant’s telephone number, including area code: +353 1232 2000

Not Applicable

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Ordinary Shares, $0.001 par value   STE   New York Stock Exchange
2.700% Senior Notes due 2031   STE/31   New York Stock Exchange
3.750% Senior Notes due 2051   STE/51   New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


Item 5.07

Submission of Matters to a Vote of Security Holders.

At the Company’s 2021 Annual General Meeting of Shareholders (“Meeting”) held on July 29, 2021, shareholders voted on the matters specified below, with the final voting results as specified. According to the certified list of shareholders, there were 85,376,813 Ordinary Shares of the Company outstanding and entitled to vote at the Meeting. There were present at the Meeting, in person or by proxy, the holders of 75,668,916 Ordinary Shares or 88.63% of the outstanding Ordinary Shares of the Company, constituting a quorum.

 

1.

The nominees named below were re-elected to the Board of Directors, each for a one-year term, and the results of the vote were as follows:

 

Nominee

   Votes for      Votes
against
     Abstentions      Broker
non-votes
 

Richard C. Breeden

     68,247,262        4,693,830        59,364        2,668,460  

Daniel A. Carestio

     72,367,309        596,036        37,111        2,668,460  

Cynthia L. Feldmann

     69,825,761        3,111,263        63,432        2,668,460  

Christopher S. Holland

     72,708,755        248,471        43,230        2,668,460  

Dr. Jacqueline B. Kosecoff

     58,179,041        14,774,137        47,278        2,668,460  

Paul E. Martin

     72,669,737        291,008        39,711        2,668,460  

Dr. Nirav R. Shah

     72,788,496        142,591        69,369        2,668,460  

Dr. Mohsen M. Sohi

     69,928,249        3,033,341        38,866        2,668,460  

Dr. Richard M. Steeves

     72,301,903        667,128        31,425        2,668,460  

 

2.

The results of a proposal to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending March 31, 2022 were as follows:

 

Votes for

     67,990,053  

Votes against

     3,945,656  

Abstentions

     3,733,207  

 

3.

The results of a proposal to appoint Ernst & Young Chartered Accountants as the Company’s statutory auditor under Irish law to hold office until the conclusion of the Company’s next Annual General Meeting were as follows:

 

Votes for

     67,991,442  

Votes against

     3,942,524  

Abstentions

     3,734,950  

 

4.

The results of a proposal to authorize the Directors of the Company or the Audit Committee to determine the remuneration of Ernst & Young Chartered Accountants as the Company’s statutory auditor under Irish law were as follows:

 

Votes for

     73,854,625  

Votes against

     1,752,422  

Abstentions

     61,869  

 

5.

The results of a proposal to approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed pursuant to the disclosure rules of the Securities and Exchange Commission, including the Compensation Discussion and Analysis and the tabular and narrative disclosure contained in the Company’s proxy statement dated June 14, 2021, were as follows:

 

Votes for

     70,427,202  

Votes against

     2,486,333  

Abstentions

     86,921  

Broker non-votes

     2,668,460  

 


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

STERIS plc
By             

/s/ J. Adam Zangerle

Name:     J. Adam Zangerle
Title:     Senior Vice President, General Counsel & Company Secretary

Dated: August 2, 2021

Shareholder Tools